vendredi 19 mai 2017

Onco Actu du 19 mai 2017

1. Biologie

Century-old tumours could shed light on rare childhood cancers [The Guardian]

3.1 Tabac

Customized, Frequent Emails Show Promise in Tobacco Cessation [ACS]

Duterte Orders Strict Smoking Ban in Philippines, and Asks Citizens to Help [NY Times]

3.3 Prévention - Vaccins

New study could boost vaccination argument for Merck's Gardasil [FiercePharma]

5. Traitements

Scientists to test Zika virus on brain tumours [Cancer Research UK]

Scientists to test whether Zika can kill brain cancer cells [Reuters]

5.10 Traitements - Essais

The future of clinical trials considered during Dean’s Lecture Series address [Stanford Medicine]

5.2 Pharma

Novartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer care [Novartis]

5.3.4 Traitements - AMM (FDA, EMA)

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer [Merck]

Pebrolizumab (Keytruda): Advanced or Metastatic Urothelial Carcinoma [FDA]

5.4 Traitements - Economie

High drug prices: Don’t let industry excuses go unchecked–or patient voices go unheard [HealthNewsReview]

Clinical trial participants should have a say in new drug pricing [STAT] ASCO (général) - Industriels

Myriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting [Myriad]

Incyte climbs on combo data for IDO inhibitor epacadostat [FierceBiotech]

Bayer to Highlight Oncology Franchise Research at ASCO 2017 [Bayer]

#ASCO17: Epizyme will hunt a quick OK for tazemetostat, despite disappointing analysts with new data [EndPoints]

5.5.16 ASCO (médecine de précision)

Number of Mutations in a Tumor Varies by Age and Type of Cancer [GUMC]

5.5.2 ASCO (sein)

ASCO: Lilly's abemaciclib vs. Pfizer's Ibrance? Too early to make a call, analysts say [FierceBiotech]

5.5.5 ASCO (gastro-intestinal)

Roche builds case for T-cell bispecific-anti-PD-L1 combo [FierceBiotech]

5.5.8 ASCO (poumon)

ASCO: Merck's Keytruda-chemo combo approach racks up more support with positive overall survival data [FierceBiotech]

6.1 Observation

Study estimates number of U.S. women living with metastatic breast cancer [NIH]

More Women Are Living Longer With Metastatic Breast Cancer, But Questions Remain [Forbes]

6.10 Politiques

Two female scientists and a militant environmentalist join Emmanuel Macron’s new government [Science]

6.10.1 Politiques (USA)

Ex-NIH director warns mooted Trump funding cuts would ‘disembowel’ U.S. research institutions [FierceBiotech]

6.6 Publications

Four in 10 biomedical papers out of China are tainted by misconduct, says new survey [Retraction Watch]